Current Headlines

  1. New Vaccines Targeting Adults Could Help Eradicate Tuberculosis
    10/15/2014

    A new study indicates that vaccines targeting teens and adults can help eliminate tuberculosis (TB) more effectively than the present TB vaccine for infants, according to a recent report in the University Herald.

  2. DelMar’s Cancer Drug Promising For Treating Chemo-Resistant Lung Cancer
    10/15/2014

    DelMar Pharmaceuticals has announced promising new clinical data from its lead cancer drug, VAL-083, demonstrating the effectiveness of this compound in the treatment of non-small cell lung cancer (NSCLC).

  3. Texas A&M On Standby For Ebola Drug Mass Production
    10/15/2014

    The Texas A&M Health Science Center is one of the three sites on standby for mass production of Z-MAPP, an investigational drug for Ebola awaiting approval from the U.S. Food and Drug Administration (FDA).

  4. Endo Locks Down $2.6B Deal To Acquire Auxilium
    10/15/2014

    After weeks of negotiations, Endo has acquired Auxilium in a deal worth $2.6 billion, a move that adds Xiaflex, Testim, and Testopel to the company’s urology and men’s health portfolios.

  5. ISPE Releases Drug Shortages Prevention Plan
    10/14/2014

    The ISPE Drug Shortages Prevention Plan is based upon ISPE’s groundbreaking 2013 ISPE Drug Shortages Survey, which provided clear evidence that mitigating shortages requires a holistic approach and careful alignment of organizational aspects – people – as well as technical aspects of process and production.

  6. Natural Molecule Can Reverse Autoimmune Disease Response
    10/13/2014

    Researchers at the Brigham and Women's Hospital (BWH) reported the results of a new study investigating a natural molecule that can be used as a potential treatment to reverse autoimmune response and disease progression.

  7. PhRMA Releases Two New Reports Detailing Cancer Research Progress
    10/13/2014

    The Pharmaceutical Research and Manufacturers of America (PhRMA) published two reports illustrating the ways in which the oncological research sector is learning from its clinical setbacks and is forming collaborations to advance the fight against cancer.

  8. DNAtrix’s Glioma Treatment Granted FDA Orphan Drug Status
    10/13/2014

    DNAtrix, a company developing modified viruses as treatment against aggressive types of cancer, announced that its DNX-2401has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of malignant glioma.

  9. Stem Cell Therapy For ALS Gets FDA’s Fast Track Designation
    10/13/2014

    The U.S. FDA has just granted BrainStorm Cell Therapeutics’ novel stem cell therapy, NurOwn, Fast Track status for the treatment of amyotrophic lateral sclerosis (ALS).

  10. U.K. Shells Out $96M For Parkinson’s, Immune System Therapies Research
    10/10/2014

    The U.K.’s Medical Research Council (MRC) will invest $96M in research over the next three years as part of its Experimental Research Challenge. $9.6M has already been awarded to three projects that will set out to study Parkinson’s disease, reduced immunity in senior citizens, and specific mechanisms of addiction, pharmaphorum reports.

Newsletter Signup
Newsletter Signup
By clicking Sign Me Up, you agree to our Terms and that you have read our Privacy Policy.